Photo illustration: Axios Visuals. Photo: Courtesy of Crowell & Moring
The FDA's controversial and unexpected decisions are injecting unnecessary uncertainty into the biotech sector, says Crowell & Moring partner Mark Cooper.
Why it matters: Without a predictable regulatory partner, biopharma investment and dealmaking could take a hit, akin to the first half of 2025.
